Damian Kelly’s Post

Only two weeks to go ⏰ Have you registered? Webinar | Getting it right first time - UK as a springboard into Europe? Join our expert panel as they explore how successful European launches can be accelerated by early engagement in the UK to achieve optimal commercial value, setting you up for success in EU HTA. By attending this webinar, delegates will: • Learn about the commercial value of early engagement  • Understand the influence of NICE in the UK and Europe • Get up to date on the most recent European processes and regulations Please note, this webinar is only available to BioPharma companies. This webinar will be recorded and distributed after the session. Follow the link to secure your free place: https://lnkd.in/d96MNKSb #webinar #events #HTA #europe #biopharma

Citeline partnered with Pharma Ignite for a roundtable to discuss the pros and cons of basing clinical trials in today’s European landscape. The free report covers: - The factors making the US a key clinical trial location, despite recent changes to European systems. - A critical element that gives clinical trials in Europe an edge over the United States. - The particular advantages offered by Eastern Europe as a clinical trial destination. - The impacts of new regulatory and process changes in Europe. Varying financial incentives for conducting clinical trials across European countries. https://lnkd.in/eS7a3yMp #clinicaltrials #europe #pharma

The Swiss healthcare system is one of the best in the world. This quality is maintained with regulations, which in turn add to the increasing complexity of the system. In addition, Switzerland's federal structure leads to greater diversity in the healthcare system at a national level. Finally, Switzerland operates independently at the heart of Europe with its own drug approval authority and processes as well as specialized institutions. Translating the many strengths of the Swiss healthcare system into economically and socially beneficial measures demands sound knowledge of Switzerland and its healthcare system. Our new series "Navigating the Swiss healthcare landscape: A comprehensive guide for biotech and pharmaceutical companies" breaks down the challenges mentioned to enable a deeper and clearer understanding of the structure of the Swiss healthcare system. Follow us on LinkedIn or visit our blog to learn more and stay up to date: https://lnkd.in/gd_AGvu9 #SwizzardPharma #SwissHealthcareMarket #MarketAccess #MarketEntry Michael Zürcher, PhD EMBA | Bettina Schelbert | Karin Senn | Luc Heller | Arne Holicki | Yves Heller | Joël Heller | Julia Mühlethaler | Mathieu Bitz

Swizzard's "why" is to bring medical innovation to Switzerland, and our goal is to guide our clients on how to navigate the Swiss healthcare landscape with success. As such, I am happy to kick-off our new post series "a comprehensive guide for biotech and pharmaceutical companies to enter the Swiss Market". Click on the second overview slide to learn what's coming soon.

Does your #CRO have a strategy to support the unique needs of small and emerging drug sponsors? This article is based on findings from our 2023 Phase II/III CRO Benchmarking — Small Pharma Market report. Read on to explore preferred provider agreements (PPAs) by sponsor company size and the key CRO selection attributes that our small sponsor (R&D <$100M) respondents look for in a clinical trial provider. https://lnkd.in/eJ-UgvwY Allucent PSI CRO AG Rho Innovaderm Research Inc. Eurofins IQVIA #biopharma #clinicaltrials #drugdevelopment

Paving the way for successful market access🏆 Interesting panel discussion with: Fredrik Olsson, CEO of Genovis Jessica Lundström, Director Market Access, Bristol Myers Squibb John Strobel, Managing Partner, LamaMed Access LLC Jonas Fredriksson, founder of XLNCE PHARMA Successfully entering foreign pharmaceutical markets requires thorough understanding of regulatory compliance, market demand, and competitive landscape. Companies must protect intellectual property, establish efficient supply chains, and form strategic local partnerships. Adapting to cultural diversity, adhering to ethical standards, and managing financial and political risks are crucial. Continuous monitoring and adaptation ensure long-term success. #GlobalForum2024

In the ever-evolving world of pharmaceuticals, Europe is a dynamic landscape with immense potential. The recent changes in regulations bring opportunities and challenges. To maximize success, think beyond the traditional boundaries and explore the holistic European lens. https://ow.ly/YvzA50Q1vzy #EuropeanPharma #InnovateInEurope #PharmaStrategies

With the ever-increasing complexity of clinical development and market dynamics, more pharma companies are under-achieving against commercialization timelines and commercial expectations. Find out how to minimize delays and maximize revenue potential with well-structured contingency plans:

Stephan Mütze and Aylin Asadian have had a great first day at OCT Barcelona today, meeting pharma and biotech associates and discussing all things clinical trial outsourcing. Did you know that CSI has experience supplying over 1,000 clinical trials, across 45 countries in Europe, North and South America and Asia? Meet our experts tomorrow at Booth 71. #OutsouringInClinicalTrials #ClinicalTrialSupply #FullSupplyChainPartner #OCTEU2024